Nanobiotix signs deal with Janssen for cancer drug NBTXR3
PARIS, FRANCE: Nanobiotix, a biotechnology company developing nanotherapeutics for cancer, has announced a global deal with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for its lead drug NBTXR3. NBTXR3 is a potential first-in-class radioenhancer…